Lung Cancer Clinical Trial

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Summary

The purpose of this study is to explore the possible links between participant characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in participants with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed, stage IV or recurrent non-small cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease
Measurable disease by CT or MRI
Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work

Exclusion Criteria:

Participants with untreated central nervous system metastases
Participants with active, known or suspected autoimmune disease
Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors)

Other protocol defined inclusion/exclusion criteria apply

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

230

Study ID:

NCT03001882

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 33 Locations for this study

See Locations Near You

Local Institution - 0006
Springdale Arkansas, 72762, United States
Local Institution - 0001
New Haven Connecticut, 06520, United States
Local Institution - 0005
Jacksonville Florida, 32256, United States
Local Institution - 0009
Atlanta Georgia, 30322, United States
Local Institution - 0003
Saint Louis Missouri, 63110, United States
Local Institution - 0038
Bronx New York, 10461, United States
Local Institution - 0002
Cleveland Ohio, 44195, United States
Local Institution - 0008
Cleveland Ohio, 44195, United States
Local Institution - 0007
Greenville South Carolina, 29607, United States
Local Institution - 0004
Nashville Tennessee, 37203, United States
Local Institution - 0017
La Louvière Hainaut, 7100, Belgium
Local Institution - 0018
Gent , 9000, Belgium
Local Institution - 0028
Gent , 9000, Belgium
Local Institution - 0027
Liege , 4000, Belgium
Local Institution - 0016
Sint-Niklaas , 9100, Belgium
Local Institution - 0036
Paris Cedex 5 , 75248, France
Local Institution - 0033
Pierre Benite , 69495, France
Local Institution - 0034
Strasbourg Cedex , 67091, France
Local Institution - 0039
Toulon , 83000, France
Local Institution - 0015
Essen , 45136, Germany
Local Institution - 0014
Immenstadt , 87509, Germany
Local Institution - 0013
Loewenstein , 74245, Germany
Local Institution - 0012
Stuttgart , 70174, Germany
Local Institution - 0023
Bergamo , 24127, Italy
Local Institution - 0025
Catania , 95123, Italy
Local Institution - 0026
Parma , 43100, Italy
Local Institution - 0024
Perugia , 06129, Italy
Local Institution - 0021
Amsterdam , 1066 , Netherlands
Local Institution - 0022
Nijmegen , 6525 , Netherlands
Local Institution - 0011
Cluj-Napoca Cluj, 40001, Romania
Local Institution - 0010
Craiova , 20054, Romania
Local Institution - 0031
Barcelona , 08908, Spain
Local Institution - 0029
Madrid , 28041, Spain
Local Institution - 0030
Madrid , 28046, Spain
Local Institution - 0032
Sevilla , 41009, Spain

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

230

Study ID:

NCT03001882

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.